ADUS Addus HomeCare Corp. SERVICES-HOME HEALTH CARE SERVICES

Addus HomeCare (ADUS) Stock: Buy, Sell, or Hold?

$126.29
+3.87 (+3.16%) ▲
5d: -0.21% 30d: +9.37% 90d: +6.97%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (54%)
Quality Score
45/100
Position
EXTENDED
30-Day Fair Range
$115.01 – $124.79
Position: EXTENDED
Forward P/E & Valuation
16.6x FAIR
vs 14.7x historical avg
Wall Street Target
$140.92
+11.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$120.03 / $131.59
Trend: Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: ADUS shows conflicting indicators. Wait for confirmation before entering.

Get Alerted When ADUS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$147.39
Based on 5.7% avg growth
INTRINSIC VALUE TODAY
$91.52
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.7x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ADUS is currently trading at $126.29, which is considered extended relative to its 30-day fair value range of $115.01 to $124.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.6) compared to its historical average (14.7). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, ADUS is in a uptrend. Immediate support is located at $120.03, while resistance sits at $131.59. The stock is showing strong short-term momentum, up 3.2% recently.

Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $140.92 (+11.6%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $115.01 - $124.79
Company Quality Score 45/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 54.3%

Trading Range & Key Levels

30-Day Trading Range $115.01 - $124.79
Current vs Trading Range EXTENDED
Support Level $120.03
Resistance Level $131.59
Current Trend Uptrend
Technical data as of Nov 10, 2026

Quantitative Signal Breakdown

  • BEARISH: Price extended above range
  • NEUTRAL: Mixed technical signals (43/100)
  • BULLISH: High volume confirmation
  • BULLISH: Strong upward momentum (+3.2%)
  • BULLISH: Trading below Wall St target ($140.92)
  • NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
  • WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 16.61
Wall Street Target $140.92 (+11.6%)
Revenue Growth (YoY) 7.0%
Earnings Growth (YoY) 24.2%
Profit Margin 7.4%
Valuation Premium vs History +4.1% premium
PE vs Historical 16.6 vs 14.7 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +4.1% (market-implied from PE analysis)
1-Year Target $131.47 (+4%)
2-Year Target $136.86 (+8%)
3-Year Target $142.47 (+13%)
3-Yr Target (if PE normalizes) (PE: 17→15) PE COMPRESSION $126.06 (0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 7.4%) $186.78 (+48%)
Base: (SPY PE: 16.6, Growth: 7.4%) $156.25 (+24%)
Bear: (PE: 14.1, Growth: 7.4%) $132.81 (+5%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 20.68 | Current EPS (TTM): $5.92
Bull Case $172.91 (+37%)
Analyst growth 28.4%, PE expands to 22.8
Base Case $157.19 (+25%)
Market implied 28.4%, PE stable at 20.7
Bear Case $83.25 (-34%)
Severe decline -20.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share ADUS Analysis

Share this live ADUS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (ADUS)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
May 14, 2026
Daily AI digest
AI Retail Discussion Summary: Addus HomeCare's Q1 earnings report showed a revenue miss, but strong growth in key areas like hospice and acquisitions. Management discussed the impact of weather and ongoing benefits from recent acquisitions.
Key Retail Themes: Company performance Management commentary
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 5:43 AM ET
Data refreshes hourly during market hours. Next update: 6:43 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for ADUS.

Create Free Account

Already have an account? Log In

Top Rated Medical Care Facilities Stocks

Top-rated stocks in Medical Care Facilities by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
THC
Tenet Healthcare Corpora…
STRONG BUY
23 analysts
$306 47 HOLD
CMPS
Compass Pathways Plc
STRONG BUY
16 analysts
$24 55 HOLD
HCA
HCA Healthcare, Inc.
BUY
26 analysts
$477 39 SELL
EHC
Encompass Health Corp
STRONG BUY
13 analysts
$156 34 SELL
CON
Concentra Group Holdings…
STRONG BUY
11 analysts
$44 41 HOLD

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive ADUS Research Pages
ADUS Technical Chart ADUS Price Prediction ADUS Intrinsic Value DCF ADUS Earnings Date ADUS Investment Advisor ADUS Fair Price Analyzer ADUS Competitors
Part B: Tradestie Flagship Market Scanners
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals